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The Challenge of Assuring Continued Post-Trial Access to
Beneficial Treatment
Christine Grady, R.N., Ph.D.*
Sam Jones has agreed to participate in a clinical trial testing an
experimental drug as a possible treatment for his chronic disease. The
primary outcome of effectiveness is a decrease in a specific disease marker
after two months of taking the drug. Soon after Sam begins to take the
drug, he reports feeling better and the level of disease marker in his blood
is significantly lower at each study interval. The study reaches its
predetermined endpoint, is stopped as planned, and the sponsor submits
an application to a regulatory agency to license the drug for this
indication. It is clear that Sam would clinically benefit from continuing to
take the drug.
Is it the responsibility of the investigator or the research sponsor to
ensure that Sam and other participants in this study continue to receive
the drug or even to provide it to them after a study ends? This question is
at the heart of recent controversy regarding post-trial benefits and may be
one of the biggest ethical challenges facing clinical investigators, especially
those involved in international research, over the next several years.
POST-TRIAL BENEFITS
Until recently, regulations and codes of research ethics have been
silent about what should happen at the conclusion of a clinical study.
Regulations and codes have focused on protecting the rights and welfare
of individuals in clinical research by requiring that the research design was
appropriate, risks were minimized, research was reviewed by an
independent body, and the participant's consent was adequately informed
* Department of Clinical Bioethics, National Institutes of Health (NIH). The author is
currently head of the section on human subject research at the NIH Department of Clinical
Bioethics. She would like to thank Reidar Lie and Zeke Emanuel for their helpful
discussions and critical review. The views expressed here are those of the author and do not
necessarily reflect those of the Clinical Center, the National Institutes of Health, the Public
Health Service, or the Department of Health and Human Services.
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and voluntary. The Common Rule in the Code of Federal Regulations
requires that investigators inform participants in advance of any
interventions or compensation that will be provided if a research
participant is injured during trial participation,' but it offers no guidance
regarding what should happen to a person like Sam. Even the forward-
looking International Ethical Guidelines for Biomedical Research Involving
Human Subjects,2 published by the Council for International Organizations
of Medical Sciences (CIOMS) in 1993, did not address the issue of what
should happen at the end of a clinical study to participants who are
receiving beneficial treatment. The CIOMS guidelines did address the
issue of compensation for research injury and also introduced the idea that
the sponsoring agency of externally sponsored research "should agree in
advance of the research that any product developed through such research
will be made reasonably available to the inhabitants of the host community
or country at the completion of successful testing."3
Controversy in the late 1990s about the ethics of international HIV
trials brought increased attention to the issue of post-trial benefits.4 Many
agreed that in order to minimize the possibility of exploiting research
participants in developing countries, a plan for how the benefits of
research would be made reasonably available to the developing country or
community was required . Most of the discussion focused on the
requirement that products proven effective through research be made
available to the wider community from which research participants were
drawn. The question of continued treatment of participants like Sam has
1. 45 C.F.R. § 46 (2003).
2. COUNCIL FOR INT'L ORG. OF MED. SC., INTERNATIONAL ETHICAL GUIDELINES FOR
BIOMEDICAL RESEARCH INVOLVING HuMAN SuBJEcTS (1993) (on file with author).
3. Id. at 45.
4. See Marcia Angell, The Ethics of Clinical Research in the Third World, 337 NEW ENG. J.
MED. 847 (1997); Peter Lurie & Sidney M. Wolfe, Unethical Trials of Interventions to Reduce
Perinatal Transmission of the Human Immunodeficiency Virus in Developing Countries, 337 NEW
ENG. J. MED. 853 (1997); Harold Varmus & David Satcher, Ethical Complexities of Conducting
Research in Developing Countries, 337 NEW ENG.J. MED. 1003 (1997).
5. See, e.g., NAT'L BIOETHICS ADVISORY COMM'N, ETHICAL AND POLICY ISSUES IN
INTERNATIONAL RESEARCH: CLINICAL TRIALS IN DEVELOPING COUNTRIES (2001) [hereinafter
NBACI; NUFFIELD COUNCIL OF BIOETHICS, THE ETHICS OF RESEARCH RELATED TO HEALTHCARE
IN DEVELOPING COUNTRIES 11 (2002), http://www.nuffieldbioethics.org/go/ourwork/
developingcountries/publication_309.html [hereinafter NUFFIELD]; Leonard H. Glantz et
al., Research in Developing Countries: Taking "Benefit" Seriously, 28 HASTINGS CENTER REP. 38
(1998); Eric M. Meslin & Harold T. Shapiro, Ethical Issues in the Design and Conduct of Clinical
Trials in Developing Countries, 345 NEW ENG.J. MED. 139 (2001).
V: 1 (2005)
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been less frequently attended to, with a few notable exceptions.6 The
challenges of assuring that products proven effective during a trial are
subsequently made reasonably available to the population in which the
product was tested are formidable.' Nonetheless, it is both practically and
ethically a different challenge than that of assuring that individual research
participants continue to receive beneficial treatments once the trial is over.
Yet, the two issues are commonly conflated."
CURRENT GUIDANCE
In the past few years, certain research ethics guidance documents,9
reports, ° and national guidelines" have begun to address the issue of
continued post-trial treatment of participants like Sam who are receiving
beneficial treatment. The Declaration of Helsinki, first published in 1964
by the World Medical Association (WMA), is internationally recognized as
a major source of ethical guidance for the conduct of clinical research."
The WMA substantially revised the Declaration of Helsinki at its fifty-
second assembly in 2000 due to intense public disagreement regarding the
6. See NBAC, supra note 5, at 12-13; COUNCIL FOR INT'L ORG. OF MED. SC.,
INTERNATIONAL ETHICAL GUIDELINES FOR BIOMEDICAL RESEARCH INVOLVING HUMAN SUBJECTS
cmt. on guideline 10 (2002) [hereinafter CIOMS 2002] ("[I]f an investigational drug has
been shown to be beneficial, the sponsor should continue to provide it to the subjects after
the conclusion of the study, and pending its approval by a drug regulatory authority.");
JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS, ETHICAL CONSIDERATIONS IN HIV
PREVENTIVE VACCINE RESEARCH 13 (2000) [hereinafter UNAIDS].
7. See Participants in the 2001 Conference on Ethical Aspects of Research in
Developing Countries, Moral Standards for Research in Developing Countries: From "Reasonable
Availability"to "Fair Benefits, "34 HASTINGS CENTER REP. 17 (2004).
8. See Editorial, One Standard, Not Two, 362 THE LANCET 1005 (2003) [hereinafter One
Standard, Not Two].
9. See, e.g., WORLD MED. ASS'N, DECLARATION OF HELSINKI (2000), http://www.wma.net/
e/policy/pdf/17c.pdf [hereinafter WMA] (clarified in 2002 and 2004); CIOMS 2002, supra
note 6.
10. See, e.g., NBAC, supra note 5; NUFFIELD, supra note 5.
11. See, e.g., CLINICAL TRIALS WORKING GROUP OF THE S. AFRICAN DEP'T OF HEALTH,
GUIDELINES FOR GOOD PRACTICE IN THE CONDUCT OF CLINICAL TRIALS IN HUMAN PARTICIPANTS
IN SOUTH AFRICA 1 9.3.5 (2000), at http://196.36.153.56/doh/docs/policy/
trials/trialscontents.html; INDIAN COUNCIL OF MED. RES., ETHICAL GUIDELINES FOR
BIOMEDICAL RESEARCH ON HUMAN SUBJECTS 27 (2000), http://icmr.nic.in/ethical.pdf; NAT'L
CONSENSUS CONF., GUIDELINES FOR THE CONDUCT OF HEALTH RESEARCH INVOLVING HUMAN
SUBJECTS IN UGANDA (1997) (on file with author).
12. WMA, supra note 9.
3
Grady: The Challenge of Assuring Continued Post-Trial Access to Beneficial Treatment
Published by Yale Law School Legal Scholarship Repository, 2005
YALE JOURNAL OF HEALTH POLICY, LAW, AND ETHICS
aforementioned international HIV trials. The extensive changes included
the addition of several new ideas that had not appeared in previous
versions of the Declaration. 13 One addition to the 2000 version of Helsinki,
Paragraph 30, directly speaks to what should happen to Sam: "At the
conclusion of the study, every patient entered into the study should be
assured of access to the best proven prophylactic, diagnostic, and
therapeutic methods identified by the study.
14
Certain paragraphs in the 2000 version of the Declaration of Helsinki,
particularly Paragraph 29 (regarding placebo-controlled trials) and
Paragraph 30 (regarding post-trial treatment of participants), have
continued to fuel considerable debate. A clarification to Paragraph 29,
issued by the WMA in 2002, attempted (some would say unsuccessfully) to
affirm a definitive stance about placebo-controlled trials.1 5 A call for
clarification or an amendment to Paragraph 30 was also considered. The
WMA voted early in 2004 not to amend Paragraph 30, but to consider
issuing a clarification. 16 In October 2004, a clarification of Paragraph 30
was issued by the WMA:
The WMA hereby reaffirms its position that it is necessary during the
study planning process to identify post-trial access by study participants to
prophylactic, diagnostic and therapeutic procedures identified as
beneficial in the study or access to other appropriate care. Post-trial access
arrangements or other care must be described in the study protocol so the
ethical review committee may consider such arrangements during its
review.17
WHAT IS THE ISSUE?
At first glance, it may appear to be common sense that if someone is
doing well on a medication or treatment, even if that treatment is
13. See Heidi P. Forster et al., The 2000 Revision of the Declaration of Helsinki: A Step
Forward or More Confusion?, 358 THE LANCET 1449 (2001).
14. WMA, supra note 9, 30.
15. Douglas P. Lackey, Clinical Research in Developing Countries: Recent Moral Arguments, 18
CADERNOS DE SAliDE PUBLICA 1455, 1457-58 (2002); Reidar K. Lie et al., The Standard of Care
Debate: The Declaration of Helsinki Versus the International Consensus Opinion, 30J. MED. ETHics
190, 190 (2004).
16. WORLD MED. ASS'N, WORKGROUP REPORT ON THE REVISION OF PARAGRAPH 30 OF THE
DECLARATION OF HELSINKI (2004), http://www.vana.net/e/ethicsunit/pdf/wg doh
jan2004.pdf [hereinafter WMA WORKGROUP REPORT].
17. WMA, supra note 9, at 5; see also Press Release, World Med. Assembly, Clarification
on Declaration of Helsinki (Oct. 11, 2004), http://www.wma.net/e/press/2004_24.htm.
V: 1 (2005)
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investigational, it should be continued. Discontinuation of such a
treatment may have poor health consequences for many research
participants, and therefore should require compelling justification. Yet
most research protocols do not include provisions to assure continued
access to products that are providing clinical benefit to individual
participants after the study concludes. Even for investigational drugs that
eventually are approved, licensed, and made available through the health
care system, there is usually a lag time during which a research participant
could benefit from continued treatment. And in some cases, individual
research participants will not be able to obtain such treatments even after
approval.
Anecdotal evidence suggests that most investigators, at the very least,
refer research participants to continued treatment through their regular
health care providers when a trial is over. However, the realities of limited
access to health care, primarily in the developing world, but also in many
communities in the United States, suggest that referral to health care
providers may often be inadequate. Research participants can also be
referred to pharmaceutical company-sponsored patient assistance
programs, which are designed to help patients obtain subsidized access to
drugs they need that would otherwise be unavailable or unaffordable.
Pharmaceutical companies sometimes pledge to continue to provide a
drug that participants are receiving in a clinical trial for a predetermined
period of time-often three to five years-and more rarely for the life of
an individual participant.18 Investigators have been known to creatively seek
out public assistance programs, social services, additional research
protocols, and other sources of funds to be able to continue to provide
beneficial drugs to research participants in the short term.19
Despite these efforts, there is no system in place for assuring
continued treatment. And the question of whose responsibility or
obligation it is to make sure a research participant continues to receive
beneficial treatment remains unsettled, as noted by the editors of The
Lancet.
The idea behind [the Declaration of Helsinki] language is
straightforward: a person who participates in a trial should have a chance
to benefit from what is learned from the trial-a principle that is
particularly important for participants in the developing world. Trial
18. See Nancy Kass & Adnan A. Hyder, Attitudes and Experiences of U.S. and Developing
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participants in wealthy nations will usually be able to get the best available
treatment after the trial is over. But in the developing world when the
researchers pack up and go home, participants can be left with nothing."0
As important as it is to recognize that research participants should
have the chance to benefit from what is learned from a trial, it is also true
that benefits can and probably should come in many other forms besides
continued receipt of treatment. In addition, the Declaration of Helsinki is
silent on who should assure continued treatment and assigning
responsibility for assuring continued treatment is not straightforward.
MORAL REASONS FOR ASSURING CONTINUED TREATMENT
If a participant is deriving clinical benefit from an investigational
therapy, withdrawing that therapy can be harmful. For many diseases,
especially those requiring chronic treatment, exacerbation of symptoms or
disease can occur if treatment is stopped. In accord with principles of non-
maleficence and beneficence, patients, including those who are being
treated as participants in research, should continue to receive a treatment
they need as long as they are benefiting from it.
Further, stopping a clinically beneficial treatment simply because a
clinical trial ends seems unfair and might contravene ethical obligations
created by enlisting people to participate in research. 21 Because research
participants accept some risk for the good of society and the advancement
of science, certain things are owed to them in return. The U.S. National
Bioethics Advisory Committee described this as 'Justice as reciprocity."
2
Also, because research participants are asked to entrust certain aspects of
their health to researchers, there is a corresponding responsibility of
researchers to care for these aspects.23 Although the basis for these
obligations may seem indisputable, the extent of the obligation-or what
exactly is owed to research participants and by whom-is at the center of
the debate. Belsky and Richardson argue that the extent of researchers'
obligation to care for participants is influenced by several factors,
including the strength of the relationship and the vulnerability of the
24participants. Participants who are ill and participate in research with the
hope of deriving some therapeutic benefit put partial trust in investigators.
20. One Standard, Not Two, supra note 8, at 1005.
21. Forster et al., supra note 13, at 1451.
22. NBAC, supra note 5, at 59.
23. See Leah Belsky & Henry S. Richardson, Medical Researchers' Ancillay Clinical Care
Responsibilities, 328 BRrr. MED.J. 1494 (2004).
24. Id. at 1495-96.
V: 1 (2005)
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Dropping them completely may be an abandonment of investigator
responsibilities and trust. A physician's role, even as clinical investigator,
includes that of advocating for the welfare of the research participant.
Exploitation is another worry in clinical research. In research,
exploitation occurs when the participant is taken unfair advantage of for
the investigator's or sponsor's benefit. Is the research participant who
receives beneficial treatment for a limited period of time exploited?
Receiving beneficial treatment through trial participation even for a finite
period of time may be perceived by participants with limited access to
health care as a good option, or at least as a better option than no
treatment at all. I would argue that it is not necessarily exploitative to offer
time-limited access to beneficial treatment through research for a willing
and informed participant. Yet, there are other moral reasons why
researchers should take steps to assure post-trial access to beneficial
treatment.
The moral obligation to assure that beneficial treatment is continued
might well be fulfilled by referring a research participant like Sam to a
physician who can prescribe the drug and, when necessary, by making
provisions through the sponsor or a pharmaceutical company to provide
the drug in the interim. But what if the drug is unlikely to be licensed in
the jurisdiction for the foreseeable future? And what if, even if the drug is
licensed, Sam or someone like him will not be able to afford it? Growth in
international collaborative research has called attention to this problem
because of the reality of limited availability and access to medical treatment
in many developing countries.25 It is also an important issue in countries
like the United States, where health care services are unevenly available.
OTHER CHALLENGES TO PROVIDING CONTINUED TREATMENT
Even if the rationale for assuring continued treatment is compelling,
the question of who should be responsible for assuring this and how it
should be accomplished remains. It has been argued that if
pharmaceutical companies and sponsors are made solely responsible for
assuring continued access to beneficial treatment, this requirement could
serve as a major disincentive for companies to engage in certain kinds of
research. 26 This could also jeopardize the future of research in places with
limited health care access,27 especially for diseases that might require
25. NBAC, supra note 5, at 59.
26. See P. G. De Roy, Helsinki and the Declaration of Helsinki, 50 WORLD MED.J. 9 (2004).
27. See Bernard P~coul et al., Access to Essential Drugs in Poor Countries: A Lost Battle, 281
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chronic or expensive treatment.28 Commentators worry about the
possibility of dampening research in developing countries where new
treatments are needed the most.'
A recent and dramatic example of this tension unfolded in a planned
study of tenofovir for possible prevention of HIV in Cambodia. The study
called for the inclusion of almost one thousand sex workers. The study was
halted when the Women's Network for Unity, a Cambodian sex workers
union, demanded a guarantee that participants would receive health care
for thirty years following conclusion of the trial. Ironically, the Asian
Pacific Network of Sex Workers concurrently denounced the trial in a
protest at the World AIDS Conference for offering participants access to
better treatment than they would have otherwise received. °
A separate question also arises about the limits of such responsibility if
it is assumed by a sponsor. In other words, how should it be decided
whether it is sufficient for a sponsor to agree to provide continued
treatment to participants for three years, for thirty years, as the Cambodian
sex workers wanted, or for participants' lifetimes? The recent WMA
clarification suggests that the adequacy of arrangements for post-trial
access to beneficial treatments should be decided by ethics review
committees.3 ' Ethics review committees still need guidance to determine
the adequacy of such arrangements for post-trial treatment in each case.
This determination should also take into consideration the need for
monitoring and administration of supplied treatments.
Previous arguments for modification or clarification of Paragraph 30
of the Declaration of Helsinki focused on the specifics of Paragraph 30 .
Some have debated the exact meaning of "best proven," and have pointed
out that a single trial almost never proves the effectiveness of an
intervention. Others have noted that an ethical requirement for assuring
post-trial treatment could never be absolute, since many research studies
JAMA 361 (1999).
28. See Helen Frankish, WVMA Postpones Decision to Amend Declaration of Helsinki, 362 THE
LANCET 963 (2003).
29. See, e.g., Jintanat Ananworanich et al., Creation of a Drug Fund for Post-Clinical Trial
Access to Antiretrovirals, 364 THE LANCET 101 (2004).
30. Jon Cohen, Cambodian Leader Throws Novel Prevention Trial into Limbo, 305 SCIENCE
1092 (2004); Marilyn Chase & Gautam Naik, Key AIDS Study in Cambodia Now in Jeopardy,
WALL ST.J., Aug. 12, 2004, at B1.
31. WMA WORKGROUP REPORT, supra note 16.
32. See WORLD MED. ASs'N, WMA SECRETARIAT REPORT ON THE REVISION OF PARAGRAPH 30
OF THE DECLARATION OF HELSINKI (2003), http://www.wma.net/e/ethicsunit/pdf/
secretariat-report-rev-paragraph30.pdf; WMIA WORKGROUP REPORT, supra note 16.
V:l1 (2005)
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are not treatment trials and it is far from clear what obligation would be
due to participants who do not benefit from the trial. How would an
obligation to assure "the best proven methods ... identified by the study
' 33
be affected if it was known that a treatment not tested in the trial is more
effective for the condition in question? All of these issues should be
clarified in available guidance documents so that researchers and research
sponsors know the extent of their obligations, and ethics review
committees can determine whether proposed arrangements are
acceptable. However, deliberations about particular details should occur
against a background commitment to finding ways to assure continued
access to beneficial treatment.
Certain commentators and reviewers have worried about the possibility
of undue inducement from continued provision of treatment.3 4 That is, if
continued access to treatment is guaranteed, the treatment access may be
so attractive that an individual might be unable to refuse participation
even if he or she wanted to. For a study that is otherwise ethical, and from
which the participant is deriving benefit and not subject to significant risk
of harm, concerns about undue inducement from continuing beneficial
treatment seem misplaced."
POSSIBLE STRATEGIES
Despite the many problems and challenges in assuring continued
treatment after a trial, there is basic agreement that this should be done.
The real challenge is to specify how this obligation should be understood
and discharged. With that in mind, I will suggest some possible strategies
to help Sam and others like him.
First, the various partners to a research study-investigators, sponsors,
communities, national health systems, international organizations-should
assume responsibility for this problem together. Possible ways of
addressing continued access for research participants who benefit from
investigational treatments should be discussed and negotiated prior to
beginning a study. Researchers and sponsors cannot ignore this issue,
believing it is someone else's problem. At the same time, researchers and
sponsors cannot be saddled with the sole responsibility of treating people
33. WMA, supra note 9.
34. See, e.g., Leah E. Hutt, Freebies for Subject 641: A Discussion of the Ethical Prospect of
Providing Drug Trial Subjects with Post-Trial Access to the Drug Tested-A Canadian Perspective, 6
HEALTH L.J. 169, 185 (1998).
35. See Ezekiel J. Emanuel, Ending Concerns About Undue Inducement, 32 J.L. MED. &
ETHICS 100 (2004).
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who ought to be receiving treatment through the regular health care
infrastructure. Expecting researchers and sponsors to fill that gap is not
only an unrealistic expectation but would also act as a powerful negative
disincentive. The aforementioned trial in Cambodia may be a good
example. Involved parties should engage in good faith negotiations before
a study begins to agree on how treatment will be assured after a study has
concluded.
Those involved in research and health care delivery should be working
together to come up with creative strategies to offer continued treatment
to research participants who need it. One example of a creative strategy
with multiple partners is the HIV Netherlands, Australia, Thailand
Research Collaboration (HIV-NAT) co-payment and sliding scale drug
fund program. HIV-NAT is a non-governmental, non-profit organization of
three collaborators: the Thai Red Cross AIDS Research Center in
Thailand, the National Centre in H1V Epidemiology and Clinical Research
in Sydney, and the International Antiviral Therapy Evaluation Centre in
Amsterdam. 6 Part of the motivation for creating the drug fund was
eloquently described in a recent publication: "Although we stated clearly in
consent forms that we could not promise post-trial drug supply, we were
compelled to take action when faced with the tragic prospect of watching
patients reversing their excellent quality of life gained while on
antiretrovirals."07 In the HIV-NAT drug fund program, patients who apply
are initially assessed and then re-assessed annually by experienced social
workers to determine their ability to pay, and the case is then reviewed by
the drug fund committee who decides on an amount to be subsidized. The
committee works with prescribing physicians to consider possible ways to
reduce costs without jeopardizing the patient and also oversees the bulk
purchase of drugs to obtain low prices. Patient support may come in the
form of cash or drugs or a combination of the two.38 Models such as this
one can be adapted for other types of trials or other areas. In any case, it is
clear that other approaches are sorely needed.
Second, the problem of post-trial access to beneficial treatments for
participants should always be considered in the context of other
considerations for ethical research. Continued treatment of research
participants with medications they receive in a trial cannot make otherwise
bad research ethical. Providing treatment to a small number of individuals
during or after a trial does not eliminate or address concerns about
36. See Ananworanich et al., supra note 29.
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exploitation. Negotiating fair benefits from research in order to minimize
exploitation of participants and communities is a necessary part of
collaborative research. 9
Third, the world health community must remain committed to finding
ways to promote better access to needed health care and treatment
globally. This will require the energy and creativity of policymakers,
scientists, clinical providers, politicians, and communities. If patients
everywhere had better access to needed treatments, continued access to
treatment at the end of a trial would be primarily a temporary issue.
Research is only one way of contributing to improved access to health care.
It does so through the application of rigorous methods to search for health
care interventions that are appropriate, affordable, safe, effective, and easy
to administer. Even those with creative strategies, like the HIV-NAT group,
articulate this larger need.40
Fourth, sponsors and researchers should take responsibility for certain
short-term solutions when appropriate. For example, sometimes it will be
necessary to provide beneficial medications to participants while awaiting
licensure, or to establish or support patient assistance programs for
expensive treatments. Continued attention to reducing the costs of
treatments for those who need them is also called for.
The goal of clinical research is to find new knowledge to improve
health and health care. Participants in clinical research contribute
invaluably to this goal. Every effort should be made to find ways to assure
that participants like Sam who are receiving beneficial treatments as part of
their clinical trial continue to receive it after the trial ends.
39. See Participants in the 2001 Conference on Ethical Aspects of Research in
Developing Countries, Fair Benefits for Research in Developing Countries, 298 SCIENCE 2133
(2002).
40. "For any developing country, long-term drug supply for patients at the end of a trial
can only realistically be sustained if the government provides it.... A drug fund should be a
temporary solution until the ultimate goal of access for all is achieved." Ananworanich et
al., supra note 29, at 102.
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